Today Peel Hunt Maintains a “Buy” Rating on Aberdeen Asset Management PLC (LON:ADN) and a GBX 420.00 Target Price

Share

Aberdeen Asset Management PLC (LON:ADN) Rating Reaffirmed

They currently have a GBX 420.00 target on Aberdeen Asset Management PLC (LON:ADN). The target price by Peel Hunt would suggest a potential upside of 35.70% from the company’s closing share price. This has been released in a recent report on Monday, 7 December.

From a total of 17 analysts covering Aberdeen Asset Management PLC (LON:ADN) stock, 3 rate it a ”Buy”, 5 a “Sell”, and 10 a ”Hold”. This means that 17% of the ratings are positive. The highest target price is GBX 430 while the lowest target price is GBX 260. The mean of all analyst targets is GBX 329.65 with a 18.96% above today’s (GBX 302.17) stock price. Aberdeen Asset Management PLC was the topic of 48 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Peel Hunt maintained shares on December 7 with “Buy” rating. Jefferies maintained shares with “Hold” rating and GBX 286 target share price in a report from a December 1. RBC Capital Markets maintained ADN stock in a recent report from December 3 with “Underperform” rating. Citigroup maintained the rating on December 1. Citigroup has a “Neutral” rating and a GBX 300 price target on shares. Finally, BNP Paribas maintained the stock with “Underperform” rating in a report issued on a December 1.

The stock decreased 0.60% or GBX 1.83 on December 4, striking GBX 302.17. Approximately shares of stock traded hands. Aberdeen Asset Management plc (LON:ADN) has declined 32.71% since May 8, 2015 and is downtrending. It has underperformed by 31.64% the S&P500.

Today Peel Hunt Maintains a

Aberdeen Asset Management PLC is United Kingdom asset management company. The company has a market cap of 4.01 billion GBP. The Firm manages assets for both institutional and retail clients. It has 13.87 P/E ratio. The firm invests across the four main asset classes of equity, fixed income, property and alternative investment strategies.

COMMENTS: